TG4050 is becoming evaluated in two Section one medical trials. It combines Transgene’s proprietary myvac system with NEC’s reducing-edge Synthetic Intelligence (AI) abilities to decide on affected person-particular neoantigens
– Information confirm that the prediction algorithm efficiently identifies immunogenic cancer mutations, even amongst a massive set of prospect mutations
– Information will be offered at impending Digital AACR 2020 Session II
Transgene (Euronext Paris: TNG), a biotech business that designs and develops virus-centered immunotherapies for the remedy of cancer, and NEC Corporation (TSE: 6701), a chief in IT and community systems, today announce that they will present details demonstrating that the prediction algorithm employed to personalize TG4050 for just about every affected person is accurate at figuring out immunogenic cancer mutations even amongst a massive set of prospect mutations. These details have been jointly generated by the Transgene, NEC and NEC Laboratories Europe GmbH teams and will be offered at the impending conference of the American Affiliation for Cancer Research (AACR) Annual Assembly 2020 (AACR Digital Annual Assembly II).
TG4050 is an individualized therapeutic vaccine centered on Transgene’s myvac technologies. It is run by NEC’s reducing-edge AI abilities. Two Section one trials with TG4050 are ongoing in Europe and in the Usa.
TG4050 has been developed to concentrate on up to 30 affected person-particular neoantigens (cancer cell mutations) which are chosen utilizing NEC’s Neoantigen Prediction System, an innovative AI technologies that has already been used in the subject of oncology. The prediction process is centered on additional than two decades of knowledge in AI and has been skilled on proprietary immune details, letting it to accurately prioritize and decide on the most immunogenic sequences.
To consider the precision of the prediction, samples from cancer patients have been gathered. Healthy and tumor tissue have been sequenced, and mutations have been identified and rated utilizing the algorithm. These have been then evaluated by measuring the frequency of T cells versus the predicted antigens. Even though preliminary, the final results generated to-date propose that the process can identify exceptional immunogenic mutation amongst a massive listing of candidates identified in the patients.
Transgene makes use of its knowledge in viral vectorization to integrate the chosen neoantigen sequences in the genome of the Modified Vaccinia virus Ankara (MVA) viral vector. The Firm has set up a special in-home superior manufacturing practice (GMP) unit focused to manufacturing the individualized batches of TG4050 necessary for the medical growth of this novel individualized therapeutic vaccine.
Title of the poster: Efficiency of neoantigen prediction for the structure of TG4050, a affected person particular neoantigen cancer vaccine
Authors: Brandon Malone, Caroline Tosch, Benoit Grellier, Kousuke Onoue, Timo Sztyler, Karola Rittner, Yoshiko Yamashita, Eric Quemeneur, Kaidre Bendjama
Session Date and Time: June 22-24, 2020
Summary/Poster Variety: 4566
The abstract can be downloaded on the AACR web page.
Resource: ACN Newswire